Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 8/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 8/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 8/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 8/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656868 | 0.95 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL5946675 | 0.94 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL8500947 | 0.94 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL2445933 | 0.94 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL113955 | 0.90 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL28605484 | 0.84 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL142514 | 0.83 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL10261559 | 0.83 | CASP3 (0.52) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14835983 | 0.83 | CASP3 (0.56) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL10383951 | 0.81 | CASP3 (0.49) | RAB9ANPC1SMN1; SMN2TSHRCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3758697-B1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | CRESTONE INC (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118772080-A | Antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-10-15 | — | — | CN | claimed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | claimed |
| CN-115109011-A | Benzothiazole compound, preparation method and application | 河北师范大学 | 2022-09-27 | — | — | CN | claimed |
| CN-118772080-A | Antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-115109011-B | Benzothiazole compound, preparation method and application | 河北师范大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-115109011-A | Benzothiazole compound, preparation method and application | 河北师范大学 | 2022-09-27 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180148438-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2018-05-31 | — | — | US | disclosed |
| US-8513291-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130102643-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP | 2013-04-25 | — | — | US | disclosed |
| EP-2576544-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | Angion Biomedica Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013043001-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2013-03-28 | — | — | WO | disclosed |
| WO-2011153192-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-4997918-A | Benzthiazolium azo dyes | CIBA-GEIGY CORPORATION (US) | 1991-03-05 | — | — | US | disclosed |
| US-4970318-A | ANTICARBINOGENIC AGENTS | PFIZER INC. (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0105031-A2 | Cationic azo dyestuffs | CIBA-GEIGY AG (CH) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | RAB9A 3493/4885NPC1 858/4885SMN1; SMN2 3698/4885 |
| US-20180148438-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | RAB9A 3493/4885NPC1 858/4885SMN1; SMN2 3698/4885 |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | CYP7A1, CYP2E1, CYP11B1 | RAB9A 3493/4885NPC1 858/4885SMN1; SMN2 3698/4885 |
| US-20130102643-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | RAB9A 3493/4885NPC1 858/4885SMN1; SMN2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.